153 related articles for article (PubMed ID: 7273032)
21. Proceedings: Immunotherapy of Moloney sarcoma virus tumours in mice with Corynebacterium parvum.
Hamilton DN; Bell PR
Br J Surg; 1974 Apr; 61(4):321. PubMed ID: 4832648
[No Abstract] [Full Text] [Related]
22. Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
Presant CA; Bartolucci AA; Smalley RV; Vogler WR
Cancer; 1979 Sep; 44(3):899-905. PubMed ID: 383276
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy and corynebacterium parvum for induction and maintenance of remission in acute myelogenous leukaemia--a controlled study.
Shetty PA; Pai VR; Jani PH; Antia PK; Shahane AD
Indian J Cancer; 1983; 20(2):119-23. PubMed ID: 6580265
[No Abstract] [Full Text] [Related]
24. [Preliminary considerations on the intravenous use of Corynebacterium parvum in the treatment of solid neoplasms].
Scheinberg MA; Sartori JP; de Pinho JG
AMB Rev Assoc Med Bras; 1979 Apr; 25(4):139-40. PubMed ID: 315598
[No Abstract] [Full Text] [Related]
25. Responsiveness of senescent mice to the antitumor properties of Corynebacterium parvum.
Yuhas JM; Ullrich RL
Cancer Res; 1976 Jan; 36(1):161-6. PubMed ID: 1247995
[TBL] [Abstract][Full Text] [Related]
26. Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.
Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Braun DW; Fortner JG; Oettgen HF
Cancer; 1981 Jul; 48(2):245-51. PubMed ID: 7016302
[TBL] [Abstract][Full Text] [Related]
27. Anti-T antibody in malignant melanoma patients. Influence of response and survival following chemotherapy--changes in serum levels following C parvum, BCG immunization.
Thatcher N; Hashmi K; Chang J; Swindell R; Crowther D
Cancer; 1980 Sep; 46(6):1378-82. PubMed ID: 7417939
[TBL] [Abstract][Full Text] [Related]
28. Chemoimmunotherapy for meningeal melanocytoma of the thoracic spinal cord. Report of a case.
Verma DS; Spitzer G; Legha S; McCredie KB
JAMA; 1979 Nov; 242(22):2435-6. PubMed ID: 490860
[No Abstract] [Full Text] [Related]
29. [Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU].
Kokoschka EM; Luger T; Micksche M
Onkologie; 1978 Jun; 1(3):98-103. PubMed ID: 362293
[TBL] [Abstract][Full Text] [Related]
30. A comparison of the toxicity of two formulations of Corynebacterium parvum in a double-blind crossover trial in patients with bronchogenic carcinoma.
Mitcheson HD; Priestman TJ
Clin Oncol; 1981 Sep; 7(3):179-82. PubMed ID: 7044635
[No Abstract] [Full Text] [Related]
31. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy of cancer with corynebacterium parvum.
Halpern B
Ann Allergy; 1978 Mar; 40(3):155-7. PubMed ID: 637374
[No Abstract] [Full Text] [Related]
33. [The use of Corynebacterium parvum in pleurodesis].
Helin T; Haahtela T
Duodecim; 1988; 104(4):262-5. PubMed ID: 3168834
[No Abstract] [Full Text] [Related]
34. The natural history of resectable metastatic melanoma (Stage IVA melanoma).
Feun LG; Gutterman J; Burgess MA; Hersh EM; Mavligit G; McBride CM; Benjamin RS; Richman SP; Murphy WK; Bodey GP; Brown BW; Mountain CF; Leavens ME; Freireich EJ
Cancer; 1982 Oct; 50(8):1656-63. PubMed ID: 7116298
[TBL] [Abstract][Full Text] [Related]
35. Monocytes and macrophages in malignant melanoma IV. Effects of C. parvum on monocyte function.
Hedley DW; Nyholm RE; Currie GA
Br J Cancer; 1979 May; 39(5):558-65. PubMed ID: 486312
[TBL] [Abstract][Full Text] [Related]
36. Coparvax for malignant effusion?
Drug Ther Bull; 1983 Oct; 21(20):79-80. PubMed ID: 6641514
[No Abstract] [Full Text] [Related]
37. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum.
MacEwen EG; Patnaik AK; Harvey HJ; Hayes AA; Matus R
Cancer Invest; 1986; 4(5):397-402. PubMed ID: 3801954
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of the effectiveness and adverse effects of a Corynebacterium parvum vaccine made in Czechoslovakia with Coparvax, a British preparation made by Wellcome, in the treatment of malignant pleural effusions].
Marel M; Melínová L; Bednár M
Cas Lek Cesk; 1989 Aug; 128(34):1071-4. PubMed ID: 2790915
[TBL] [Abstract][Full Text] [Related]
39. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
40. Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.
Thatcher N; Wagstaff J; Mene A; Smith D; Orton C; Craig P
Eur J Cancer Clin Oncol; 1986 Aug; 22(8):1009-14. PubMed ID: 3770045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
